These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37766102)

  • 61. Determination of T cell response against XBB variants in adults who received either monovalent wild-type inactivated whole virus or mRNA vaccine or bivalent WT/BA.4-5 COVID-19 mRNA vaccine as the additional booster.
    Tang YS; Tan CW; Chong KC; Chen C; Sun Y; Yiu K; Ling KC; Chan KKP; Peiris M; Mok CKP; Hui DS
    Int J Infect Dis; 2024 Oct; 149():107271. PubMed ID: 39426493
    [TBL] [Abstract][Full Text] [Related]  

  • 62. COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood.
    Govindaraj S; Cheedarla N; Cheedarla S; Irby LS; Neish AS; Roback JD; Smith AK; Velu V
    Front Immunol; 2023; 14():1211558. PubMed ID: 37465682
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray.
    Springer DN; Höltl E; Prüger K; Puchhammer-Stöckl E; Aberle JH; Stiasny K; Weseslindtner L
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250907
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages.
    Touret F; Giraud E; Bourret J; Donati F; Tran-Rajau J; Chiaravalli J; Lemoine F; Agou F; Simon-Lorière E; van der Werf S; de Lamballerie X
    iScience; 2023 Apr; 26(4):106413. PubMed ID: 36968074
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters.
    Halfmann PJ; Iwatsuki-Horimoto K; Kuroda M; Hirata Y; Yamayoshi S; Iida S; Uraki R; Ito M; Ueki H; Furusawa Y; Sakai-Tagawa Y; Kiso M; Armbrust T; Spyra S; Maeda K; Wang Z; Imai M; Suzuki T; Kawaoka Y
    Commun Biol; 2024 Mar; 7(1):331. PubMed ID: 38491227
    [TBL] [Abstract][Full Text] [Related]  

  • 66. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB.
    He Q; Wu L; Xu Z; Wang X; Xie Y; Chai Y; Zheng A; Zhou J; Qiao S; Huang M; Shang G; Zhao X; Feng Y; Qi J; Gao GF; Wang Q
    Cell Rep Med; 2023 Apr; 4(4):100991. PubMed ID: 37019110
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reduced maternal immunity and vertical transfer of immunity against SARS-CoV-2 variants of concern with COVID-19 exposure or initial vaccination in pregnancy.
    Boelig RC; Chaudhury S; Gromowski GD; Mayer S; King J; Aghai ZH; Bergmann-Leitner E
    Front Immunol; 2023; 14():1216410. PubMed ID: 37753075
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
    Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S
    Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
    Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
    Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants.
    Faraone JN; Qu P; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    Cell Rep Med; 2023 May; 4(5):101049. PubMed ID: 37148877
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
    Carr EJ; Wu MY; Gahir J; Harvey R; Townsley H; Bailey C; Fowler AS; Dowgier G; Hobbs A; Herman L; Ragno M; Miah M; Bawumia P; Smith C; Miranda M; Mears HV; Adams L; Haptipoglu E; O'Reilly N; Warchal S; Sawyer C; Ambrose K; Kelly G; Beale R; Papineni P; Corrah T; Gilson R; Gamblin S; Kassiotis G; Libri V; Williams B; Swanton C; Gandhi S; Lv Bauer D; Wall EC;
    Lancet Infect Dis; 2023 Jul; 23(7):781-784. PubMed ID: 37290472
    [No Abstract]   [Full Text] [Related]  

  • 73. Omicron (B.1.1.529) variant and its subvariants and lineages may lead to another COVID-19 wave in the world? -An overview of current evidence and counteracting strategies.
    Sah R; Rais MA; Mohanty A; Chopra H; Chandran D; Bin Emran T; Dhama K
    Int J Surg Open; 2023 Jun; 55():100625. PubMed ID: 37255735
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Protection of Omicron Bivalent Vaccine, Previous Infection, and Their Induced Neutralizing Antibodies Against Symptomatic Infection With Omicron XBB.1.16 and EG.5.1.
    Yamamoto S; Matsuda K; Maeda K; Mizoue T; Horii K; Okudera K; Tan T; Oshiro Y; Inamura N; Nemoto T; S Takeuchi J; Konishi M; Sugiyama H; Aoyanagi N; Sugiura W; Ohmagari N
    Open Forum Infect Dis; 2024 Sep; 11(9):ofae519. PubMed ID: 39319092
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An omicron-specific neutralizing antibody test predicts neutralizing activity against XBB 1.5.
    Varvel S; Galdzicka M; Nystrom S; Liu H; Chen G; Ragan I; Shabahang S
    Front Immunol; 2024; 15():1334250. PubMed ID: 38322270
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of a booster dose of BNT162b2 on spike-binding antibodies to SARS-CoV-2 Omicron BA.2, BA.3, BA.4 and BA.5 subvariants in infection-naïve and previously-infected individuals.
    Kuzel TG; Fu J; Anderson M; Stec M; Boler M; Behun D; Gosha A; Cloherty G; Landay A; Moy J
    Vaccine; 2023 Jan; 41(4):879-882. PubMed ID: 36572601
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters.
    Lasrado N; Collier AY; Miller J; Hachmann NP; Liu J; Sciacca M; Wu C; Anand T; Bondzie EA; Fisher JL; Mazurek CR; Patio RC; Powers O; Rodrigues SL; Rowe M; Surve N; Ty DM; Korber B; Barouch DH
    bioRxiv; 2023 Jan; ():. PubMed ID: 36747640
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2/5 subvariants in the upper and lower respiratory tract.
    Hu B; Chan JF; Liu Y; Liu H; Chen YX; Shuai H; Hu YF; Hartnoll M; Chen L; Xia Y; Hu JC; Yuen TT; Yoon C; Hou Y; Huang X; Chai Y; Zhu T; Shi J; Wang Y; He Y; Cai JP; Zhou J; Yuan S; Zhang J; Huang JD; Yuen KY; To KK; Zhang BZ; Chu H
    EBioMedicine; 2024 Jan; 99():104916. PubMed ID: 38101297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.